CytoDyn (CYDY) Change in Receivables (2021)

CytoDyn's (CYDY) quarterly Change in Receivables came in at $184000.0 in Q4 2021, up 348.78% on a QoQ basis from $41000.0 in Q3 2021.

CytoDyn (CYDY) Change in Receivables (2021) Analysis & Trends

CytoDyn (CYDY) has 1 years of Change in Receivables data on file, last reported at $184000.0 in Q4 2021.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Change in Receivables (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn	140.20 Mn
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn	838.50 Mn
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn	-
4	Revolution Medicines	43.64 Bn	43.64 Bn	-	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn	117.58 Mn
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn	-483,662.49
7	Royalty Pharma	33.72 Bn	35.84 Bn	-	-
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn	31.60 Mn
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn	37.16 Mn
10	CytoDyn	258.01 Mn	258.01 Mn	-	-

Download Data